Sino Biological finalizes the acquisition of SignalChem Biotech, strengthening global presence and expanding product portfolio

Sino Biological, Inc. ("Sino Biological" or the "Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, specializing in biological research reagents and related technical contract research services, has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc. (“SCB” or "SignalChem”). Sino Biological has acquired 100% of SCB shares in a deal valued at $48 M USD, inclusive of all assets, assumed indebtedness, and net of cash deposits.

SignalChem Biotech Inc. is renowned for its specialized bioactive enzymes, including kinases, proteases, phosphatases, ubiquitin and epigenetic enzymes. Over the past two decades, SCB has established proprietary production and quality control platforms, setting industry standards for the development and production of high-quality bioactive enzyme proteins to support scientists from basic research through drug discovery and development. Now operating as a wholly-owned subsidiary of Sino Biological, SCB will bring exclusive expertise in enzyme production to the company’s existing technology platforms.

The strategic synergy between Sino Biological and SignalChem enables the provision of a broader range of products and research services, supporting the wider life sciences community and facilitating the discovery and development of novel treatments, vaccines and diagnostic platforms.

SignalChem is at the scientific forefront of enzyme bioreagent development and production, as well as enzyme-based compound screening technologies. The acquisition of SCB further strengthens Sino Biological’s robust presence in bioactive recombinant proteins and related contract research services,

Dr. Jie Zhang, President and General Manager, Sino Biological

"We are excited to join forces with Sino Biological and embark on this new chapter of growth and collaboration," said Mr. Jun Yan, co-founder, president and CEO of SignalChem Biotech. "Together, we have a unique opportunity to leverage our complementary strengths and resources to accelerate innovation and better serve the scientific community. We look forward to combining our expertise to develop novel solutions that address the complex challenges facing researchers around the world.”

Sino Biological remains committed to maintaining the high standards of quality, reliability, and customer satisfaction throughout the integration process. Customers can expect continued access to the same high-quality products and services they have come to rely on, backed by the combined expertise and resources of Sino Biological and SignalChem Biotech.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2024, April 29). Sino Biological finalizes the acquisition of SignalChem Biotech, strengthening global presence and expanding product portfolio. News-Medical. Retrieved on June 13, 2024 from https://www.news-medical.net/news/20240429/Sino-Biological-finalizes-the-acquisition-of-SignalChem-Biotech-strengthening-global-presence-and-expanding-product-portfolio.aspx.

  • MLA

    Sino Biological Inc.. "Sino Biological finalizes the acquisition of SignalChem Biotech, strengthening global presence and expanding product portfolio". News-Medical. 13 June 2024. <https://www.news-medical.net/news/20240429/Sino-Biological-finalizes-the-acquisition-of-SignalChem-Biotech-strengthening-global-presence-and-expanding-product-portfolio.aspx>.

  • Chicago

    Sino Biological Inc.. "Sino Biological finalizes the acquisition of SignalChem Biotech, strengthening global presence and expanding product portfolio". News-Medical. https://www.news-medical.net/news/20240429/Sino-Biological-finalizes-the-acquisition-of-SignalChem-Biotech-strengthening-global-presence-and-expanding-product-portfolio.aspx. (accessed June 13, 2024).

  • Harvard

    Sino Biological Inc.. 2024. Sino Biological finalizes the acquisition of SignalChem Biotech, strengthening global presence and expanding product portfolio. News-Medical, viewed 13 June 2024, https://www.news-medical.net/news/20240429/Sino-Biological-finalizes-the-acquisition-of-SignalChem-Biotech-strengthening-global-presence-and-expanding-product-portfolio.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer